This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

What predicts cognitive decline in de novo Parkinson’s disease?


Arnaldi, Dario, Campus, Claudio, Ferrara, Michela, Famà, Francesco, Picco, Agnese, De Carli, Fabrizio, Accardo, Jennifer, Brugnolo, Andrea, Sambuceti, Gianmario, Morbelli, Silvia, Nobili, Flavio


Neurobiology Of Aging, Volume: 33, No.: 6, Pages.: 1127.e11-20

Year of Publication



Subtle cognitive impairment can be detected in early Parkinson’s disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an average follow-up time of about 4 years. Decline both in executive (R(2) = 0.54; p = 0.0001) and visuospatial (R(2) = 0.56; p = 0.0001) functions was predicted by the couple of Unified Parkinson’s Disease Rating Scale (UPDRS)-III score and caudate dopamine transporter (DAT) uptake in the less affected hemisphere (LAH). Verbal memory and language decline was predicted instead by caudate DAT uptake and brain perfusion in a posterior parieto-temporal area of the less affected hemisphere (R(2) = 0.42; p = 0.0005). No significant effect was shown for age, baseline neuropsychological scores, and levodopa equivalent dose at follow-up. The combined use of clinical structured examination and brain functional assessment by means of dual single photon emission computed tomography imaging appears as a powerful approach to predict cognitive decline in de novo PD patients.; Copyright © 2012 Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Arnaldi_2012, doi = {10.1016/j.neurobiolaging.2011.11.028}, url = {}, year = 2012, month = {jun}, publisher = {Elsevier {BV}}, volume = {33}, number = {6}, pages = {1127.e11--1127.e20}, author = {Dario Arnaldi and Claudio Campus and Michela Ferrara and Francesco Fam{`{a}} and Agnese Picco and Fabrizio De Carli and Jennifer Accardo and Andrea Brugnolo and Gianmario Sambuceti and Silvia Morbelli and Flavio Nobili}, title = {What predicts cognitive decline in de novo Parkinson{textquotesingle}s disease?}, journal = {Neurobiology of Aging} }


aged, cognition disorders, epidemiology, female, humans, male, methods, middle aged, parkinson disease, predictive value of tests, psychology, radionuclide imaging, tomography emissioncomputed singlephoton

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Before and After Study

Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Neuroimaging (e.g. MRI, PET, CAT etc.)